



VAXESS
technologies

Engineering Immunity for All

Vaxess is transforming efficacy and access for vaccines and therapeutics.



26

Employees

2

Partners

10

Patent Families

\$21M

Non-dilutive



\$43M

VC Funding


RACAPITAL



THE VACCINATION INSPIRATION

Pathogens enter via barrier tissues and infection persists over weeks.


The adaptive immune response evolves by pathogen protein exposure over the course of the infection period.



THE VACCINATION DISCONNECTION

Traditional vaccines are administered by bolus into non-barrier tissue and, despite antigen trafficking and an innate immune response, antigens are cleared from the body in <2 days.


The body doesn't have sufficient exposure time to mount an optimal or broad humoral or T-cell response.



ACCESS ISSUES

Vaccines require complex logistics, from cold shipment through the need for highly trained administrators.

A shelf-stable, simple-to-administer vaccine would improve access in the US and around the world.




Introducing MIMIX Patch

Smart-release vaccines that mimic infections.

- Detaching microneedle tips
- Sustained presentation
- To immune-cell rich epithelia – gateway for pathogens
- Simple administration, no needles
- Peel off after just minutes





[Click Here for YouTube Video](#)

How it works: The clear center of the MIMIX™ smart release needle dissolves rapidly upon entering the skin, **implanting the slow-release tip and enabling therapeutic release for months.**




1mm

MIMIX-Flu Enhances Protective Efficacy Against Drifted Strains of Influenza


7

Immunization with 2018-19 influenza vaccine

Challenge with 2009 H1N1 strain (A/California/04/2009)



MIMIX Clinical POC Program with COVID-18 and Flu Antigens Underway 8



¹In-house Development with conventional current seasonal flu epitope API from GC Pharma

²In-house Development with NIH subunit recombinant COVID-19 spike protein antigen

³In-house Development with off-patent immunological molecule

Proprietary Programs

- MIMIX-COVID-19
 - To accelerate to approvals
 - For introduction to all world's populations
- MIMIX-Flu seasonal flu
 - To optimize for supplementation of seasonal flu vaccine options

New MIMIX™ Vaccine Programs

- Partner's choice of pathogen
 - Co-develop immunologically superior products
 - Reach all relevant populations
 - Alternative bioactive forms
e.g., mRNA, cDNA, killed virus

MIMIX™ Outside of I.D. Vaccines

- E.g., immunotherapy of cancer



VAXESS
technologies

Engineering Immunity for All

Vaxess is transforming efficacy and access for vaccines and therapeutics.

Michael Schrader, CEO
Michael@Vaxess.com

